Trump's protectionism might be a bitter pill for Irish pharma sector
Novo Nordisk is investing €432m to expand manufacturing capacity in Athlone.
The IDA, which attracts foreign companies to Ireland, has included in its mid-year report Novo Nordisk's €432m investment in manufacturing capacity in Athlone. The site is the focal point of the Danish company's Irish operations. Novo Nordisk is scaling up the production of an oral version of its GLP-1 medicines, such as the Wegovy pill. This pill version is only for markets outside the United States.
Also, in March, Novo Nordisk announced plans to expand its oral biologic pipeline in the US, investing $2.1bn (€1.83bn) with Vivtex Corporation, which includes obesity therapy Wegovy (semaglutide). This investment is driven by the Trump administration's threat to slap import duties on any pharma company that does not invest and manufacture in the US.






